Polymer- and lipid-based nanoparticle therapeutics for the treatment of liver diseases

Summary Liver diseases, particularly hepatitis B virus infections, liver cirrhosis and hepatocellular carcinoma continue to pose a significant health challenge worldwide due to the dire lack of curative treatment options besides liver resection and transplantation. Nanoparticle therapeutics, comprising of drugs, nucleic acids or proteins in association with a carrier, have emerged as safe and efficient systems in the treatment of the respective liver diseases. This review describes targeting strategies employed in relation to liver anatomy and disease etiologies, summarizes recent advances in the field and discusses the challenges and future perspectives for the effective treatment of liver diseases using polymer- and lipid-based nanoparticle therapeutics.

[1]  H. El‐Serag,et al.  Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. , 2007, Gastroenterology.

[2]  S. Nie,et al.  Therapeutic Nanoparticles for Drug Delivery in Cancer Types of Nanoparticles Used as Drug Delivery Systems , 2022 .

[3]  G. Cheon,et al.  Systemic and specific delivery of small interfering RNAs to the liver mediated by apolipoprotein A-I. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  P. Terpstra,et al.  A novel lipid-based drug carrier targeted to the non-parenchymal cells, including hepatic stellate cells, in the fibrotic livers of bile duct ligated rats. , 2007, Biochimica et biophysica acta.

[5]  A. R. Kulkarni,et al.  Paclitaxel-loaded poly(gamma-glutamic acid)-poly(lactide) nanoparticles as a targeted drug delivery system for the treatment of liver cancer. , 2006, Biomaterials.

[6]  George Kitis,et al.  Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. , 2006, Gastroenterology.

[7]  S. Tashiro,et al.  Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report. , 1983, European journal of cancer & clinical oncology.

[8]  E. Wisse,et al.  Insulinlike growth factor—ii/mannose 6‐phosphate receptor is expressed on ccl4‐exposed rat fat‐storing cells and facilitates activation of latent transforming growth factor‐β in cocultures with sinusoidal endothelial cells , 1995 .

[9]  Jun Wang,et al.  Functionalized micelles from block copolymer of polyphosphoester and poly(epsilon-caprolactone) for receptor-mediated drug delivery. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[10]  S. Kawakami,et al.  Novel PEG-matrix metalloproteinase-2 cleavable peptide-lipid containing galactosylated liposomes for hepatocellular carcinoma-selective targeting. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[11]  Eun-Mi Kim,et al.  Superparamagnetic iron oxide nanoparticles-loaded chitosan-linoleic acid nanoparticles as an effective hepatocyte-targeted gene delivery system. , 2009, International journal of pharmaceutics.

[12]  J. Kamps,et al.  Interaction of targeted liposomes with primary cultured hepatic stellate cells: Involvement of multiple receptor systems. , 2006, Journal of hepatology.

[13]  J. Hedrick,et al.  Organocatalytic ring-opening polymerization. , 2007, Chemical reviews.

[14]  Y. Liaw.  Natural history of chronic hepatitis B virus infection and long‐term outcome under treatment , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[15]  E. Wisse,et al.  The role of liver sinusoidal cells in hepatocyte-directed gene transfer. , 2010, The American journal of pathology.

[16]  P. Chow,et al.  Thermoresponsive core–shell magnetic nanoparticles for combined modalities of cancer therapy , 2009, Nanotechnology.

[17]  J. Nah,et al.  Galactosylated chitosan-graft-polyethylenimine as a gene carrier for hepatocyte targeting , 2007, Gene Therapy.

[18]  V. Mosqueira,et al.  Nanotechnology applied to the treatment of malaria. , 2010, Advanced drug delivery reviews.

[19]  Zi-yu Wang,et al.  Nanosized As2O3/Fe2O3 complexes combined with magnetic fluid hyperthermia selectively target liver cancer cells. , 2009, World journal of gastroenterology.

[20]  M. Dewhirst,et al.  Hyperthermia mediated liposomal drug delivery , 2006, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[21]  D. Lavanchy,et al.  Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures , 2004, Journal of viral hepatitis.

[22]  G. Dore,et al.  Hepatitis B‐related hepatocellular carcinoma: epidemiological characteristics and disease burden , 2009, Journal of viral hepatitis.

[23]  Z. Ye,et al.  Targeted delivery of a triplex-forming oligonucleotide to hepatic stellate cells. , 2005, Biochemistry.

[24]  A. Gouw,et al.  Targeting 15d-Prostaglandin J2 to Hepatic Stellate Cells: Two Options Evaluated , 2007, Pharmaceutical Research.

[25]  C. Xie,et al.  Using anti-VEGF McAb and magnetic nanoparticles as double-targeting vector for the radioimmunotherapy of liver cancer. , 2006, Cancer letters.

[26]  Xian‐Zheng Zhang,et al.  Biotinylated transferrin/avidin/biotinylated disulfide containing PEI bioconjugates mediated p53 gene delivery system for tumor targeted transfection. , 2010, Biomaterials.

[27]  M. Manns,et al.  Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. , 2002, Gastroenterology.

[28]  Y. Oh,et al.  Suppression of hepatitis B virus-derived human hepatocellular carcinoma by NF-κB-inducing kinase-specific siRNA using liver-targeting liposomes , 2009, Archives of pharmacal research.

[29]  S. Tashiro,et al.  Selective targeting of anti‐cancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium , 1984, Cancer.

[30]  C. Chu,et al.  Hepatitis B virus infection , 2009, The Lancet.

[31]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[32]  J. Nah,et al.  SPION-loaded chitosan-linoleic acid nanoparticles to target hepatocytes. , 2009, International journal of pharmaceutics.

[33]  N. Borys,et al.  Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer , 2009 .

[34]  R. Mahato,et al.  HPMA polymer-based site-specific delivery of oligonucleotides to hepatic stellate cells. , 2009, Bioconjugate chemistry.

[35]  Hongxuan He,et al.  Self-assembled nanoparticle drug delivery systems from galactosylated polysaccharide-doxorubicin conjugate loaded doxorubicin. , 2010, International journal of biological macromolecules.

[36]  R. Takkenberg,et al.  New developments in antiviral therapy for chronic hepatitis B , 2010, Vox sanguinis.

[37]  B. Ahn,et al.  Targeted delivery of siRNA against hepatitis C virus by apolipoprotein A-I-bound cationic liposomes. , 2009, Journal of hepatology.

[38]  G. Béréziat,et al.  Selective channelling of arachidonic and linoleic acids into glycerolipids of rat hepatocytes in primary culture. , 1988, Biochemical Journal.

[39]  H. Sung,et al.  Preparation of nanoparticles composed of poly(gamma-glutamic acid)-poly(lactide) block copolymers and evaluation of their uptake by HepG2 cells. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[40]  C. Cho,et al.  Galactosylated chitosan-graft-dextran as hepatocyte-targeting DNA carrier. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[41]  D. Meijer,et al.  The Antiproliferative Drug Doxorubicin Inhibits Liver Fibrosis in Bile Duct-Ligated Rats and Can Be Selectively Delivered to Hepatic Stellate Cells in Vivo , 2006, Journal of Pharmacology and Experimental Therapeutics.

[42]  C. Angeletti,et al.  Fatty acid uptake and metabolism in Hep G2 human-hepatoma cells , 1995, Molecular and Cellular Biochemistry.

[43]  T. Akaike,et al.  Functional evaluation of poly-(N-ρ-vinylbenzyl-O-β-Dgalactopyranosyl-[1-4]-D-gluconamide)(PVLA) as a liver specific carrier , 2000, Journal of biomaterials science. Polymer edition.

[44]  T. Konno,et al.  Targeted chemotherapy for unresectable primary and metastatic liver cancer. , 1994, Acta oncologica.

[45]  Lei Wang,et al.  Pegylated immuno-lipopolyplexes: A novel non-viral gene delivery system for liver cancer therapy. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[46]  A. Lok,et al.  Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. , 2007, Gastroenterology.

[47]  K. Longmuir,et al.  Liposomal delivery of doxorubicin to hepatocytes in vivo by targeting heparan sulfate. , 2009, International journal of pharmaceutics.

[48]  J. Kamps,et al.  Effects of a New Bioactive Lipid-Based Drug Carrier on Cultured Hepatic Stellate Cells and Liver Fibrosis in Bile Duct-Ligated Rats , 2007, Journal of Pharmacology and Experimental Therapeutics.

[49]  K. Ishihara,et al.  Selective targeting by preS1 domain of hepatitis B surface antigen conjugated with phosphorylcholine‐based amphiphilic block copolymer micelles as a biocompatible, drug delivery carrier for treatment of human hepatocellular carcinoma with paclitaxel , 2009, International journal of cancer.

[50]  D. Rockey.  Current and future anti-fibrotic therapies for chronic liver disease. , 2008, Clinics in liver disease.

[51]  B. McMahon,et al.  Chronic hepatitis B. , 2002, The New England journal of medicine.

[52]  V. Rogiers,et al.  Prolonged gene silencing in hepatoma cells and primary hepatocytes after small interfering RNA delivery with biodegradable poly(β‐amino esters) , 2008, The journal of gene medicine.

[53]  Junji Kato,et al.  Resolution of liver cirrhosis using vitamin A–coupled liposomes to deliver siRNA against a collagen-specific chaperone , 2008, Nature Biotechnology.

[54]  H. Maeda,et al.  Exploiting the enhanced permeability and retention effect for tumor targeting. , 2006, Drug discovery today.

[55]  D. Stolz,et al.  Bifunctional compounds for targeted hepatic gene delivery , 2007, Gene Therapy.

[56]  A. Zhu.  Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? , 2006, The oncologist.

[57]  In-Kyu Park,et al.  Asialoglycoprotein receptor targeted gene delivery using galactosylated polyethylenimine-graft-poly(ethylene glycol): in vitro and in vivo studies. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[58]  R. Bataller,et al.  Reduction of advanced liver fibrosis by short‐term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats , 2010, Hepatology.

[59]  Liangfang Zhang,et al.  Therapeutic nanoparticles to combat cancer drug resistance. , 2009, Current drug metabolism.

[60]  S. W. Kim,et al.  A new synthesis of galactose-poly(ethylene glycol)-polyethylenimine for gene delivery to hepatocytes. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[61]  R. Löbenberg,et al.  Targeted delivery of nanoparticles for the treatment of lung diseases. , 2008, Advanced drug delivery reviews.

[62]  M. Gottesman,et al.  MDR1 gene expression: its effect on drug resistance to doxorubicin in human hepatocellular carcinoma cell lines. , 1994, Journal of the National Cancer Institute.

[63]  J. Bruix,et al.  Molecular targeted therapies in hepatocellular carcinoma , 2008, Hepatology.

[64]  D. Ganem,et al.  Hepatitis B virus infection--natural history and clinical consequences. , 2004, The New England journal of medicine.

[65]  J. Llovet,et al.  Systematic review: evidence‐based management of hepatocellular carcinoma – an updated analysis of randomized controlled trials , 2006, Alimentary pharmacology & therapeutics.

[66]  D. Nelson,et al.  Review article: the management of hepatocellular carcinoma , 2010, Alimentary pharmacology & therapeutics.

[67]  A. Kondo,et al.  Nanoparticles for the delivery of genes and drugs to human hepatocytes , 2003, Nature Biotechnology.

[68]  Xian‐Zheng Zhang,et al.  Porphyrin and Galactosyl Conjugated Micelles for Targeting Photodynamic Therapy , 2009, Pharmaceutical Research.

[69]  D. Treré,et al.  The asialoglycoprotein receptor in human hepatocellular carcinomas: its expression on proliferating cells , 1999, British Journal of Cancer.

[70]  D. Kerr,et al.  Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  J. Wang,et al.  Cyclic Arg-Gly-Asp Peptide-Labeled Liposomes for Targeting Drug Therapy of Hepatic Fibrosis in Rats , 2007, Journal of Pharmacology and Experimental Therapeutics.

[72]  Mei-qing Feng,et al.  Liver targeting and anti-HBV activity of reconstituted HDL-acyclovir palmitate complex. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[73]  T. Park,et al.  Galactosylated polyethylenimine-graft-poly(vinyl pyrrolidone) as a hepatocyte-targeting gene carrier. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[74]  J. Bruix,et al.  Management of hepatocellular carcinoma , 2005, Hepatology.

[75]  C. Steer,et al.  Nanocapsule-delivered Sleeping Beauty mediates therapeutic Factor VIII expression in liver sinusoidal endothelial cells of hemophilia A mice. , 2009, The Journal of clinical investigation.

[76]  Min Liu,et al.  Effect of hepatocyte growth factor encapsulated in targeted liposomes on liver cirrhosis. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[77]  W. Stremmel,et al.  Evidence for a novel keratinocyte fatty acid uptake mechanism with preference for linoleic acid: comparison of oleic and linoleic acid uptake by cultured human keratinocytes, fibroblasts and a human hepatoma cell line. , 1994, Biochimica et biophysica acta.

[78]  F. Kratz,et al.  Doxorubicin coupled to lactosaminated albumin: Effects on rats with liver fibrosis and cirrhosis. , 2006, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[79]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[80]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[81]  I. Hyodo,et al.  Distribution of asialoglycoprotein receptor in human hepatocellular carcinoma. , 2008, Liver.

[82]  Sangjin Park,et al.  Drug-loaded superparamagnetic iron oxide nanoparticles for combined cancer imaging and therapy in vivo. , 2008, Angewandte Chemie.

[83]  J. Llovet,et al.  Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. , 2010, Annual review of medicine.

[84]  Ching-Lung Lai,et al.  Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. , 2006, The New England journal of medicine.

[85]  Y. Bi,et al.  Uptake of albumin nanoparticle surface modified with glycyrrhizin by primary cultured rat hepatocytes. , 2005, World journal of gastroenterology.

[86]  Yaping Li,et al.  The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. , 2009, Biomaterials.

[87]  B. McMahon,et al.  Chronic hepatitis B , 2001, Hepatology.

[88]  Jing Zhang,et al.  A specific drug targeting system based on polyhydroxyalkanoate granule binding protein PhaP fused with targeted cell ligands. , 2008, Biomaterials.

[89]  Baorui Liu,et al.  Superior antitumor efficiency of cisplatin-loaded nanoparticles by intratumoral delivery with decreased tumor metabolism rate. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[90]  G. Koning,et al.  On the mechanism of hepatic transendothelial passage of large liposomes , 1999, FEBS letters.

[91]  Ji-Hee Kim,et al.  Multifunctional doxorubicin loaded superparamagnetic iron oxide nanoparticles for chemotherapy and magnetic resonance imaging in liver cancer. , 2010, Biomaterials.

[92]  Felix Kratz,et al.  Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[93]  A. Maruyama,et al.  Receptor-mediated cell modulator delivery to hepatocyte using nanoparticles coated with carbohydrate-carrying polymers. , 2001, Biomaterials.

[94]  A. Gressner,et al.  Dominant-negative soluble PDGF-β receptor inhibits hepatic stellate cell activation and attenuates liver fibrosis , 2004, Laboratory Investigation.

[95]  S. Zou,et al.  Effect of targeted magnetic nanoparticles containing 5-FU on expression of bcl-2, bax and caspase 3 in nude mice with transplanted human liver cancer. , 2007, World journal of gastroenterology.

[96]  Q. Ping,et al.  Preparation and evaluation of N-caproyl chitosan nanoparticles surface modified with glycyrrhizin for hepatocyte targeting , 2009, Drug development and industrial pharmacy.

[97]  G. Navarro,et al.  In vivo targeted gene delivery by cationic nanoparticles for treatment of hepatocellular carcinoma , 2009, The journal of gene medicine.

[98]  D. Schuppan,et al.  Successful Targeting to Rat Hepatic Stellate Cells Using Albumin Modified with Cyclic Peptides That Recognize the Collagen Type VI Receptor* , 2000, The Journal of Biological Chemistry.

[99]  S. Fan,et al.  Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response. , 2000, American journal of clinical pathology.

[100]  M. Chevallier,et al.  Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo. , 2005, Journal of hepatology.

[101]  Jinwoo Cheon,et al.  All-in-one target-cell-specific magnetic nanoparticles for simultaneous molecular imaging and siRNA delivery. , 2009, Angewandte Chemie.

[102]  Zhi-Feng Gan,et al.  Preparation and properties of a novel drug delivery system with both magnetic and biomolecular targeting , 2009, Journal of materials science. Materials in medicine.

[103]  M. Torbenson,et al.  PEG-b-PPA/DNA micelles improve transgene expression in rat liver through intrabiliary infusion. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[104]  Huy Trinh,et al.  Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. , 2008, The New England journal of medicine.

[105]  Y. Kato,et al.  Lactosaminated and intact N-succinyl-chitosans as drug carriers in liver metastasis. , 2001, International journal of pharmaceutics.

[106]  Alshakim Nelson,et al.  Synthesis of a family of amphiphilic glycopolymers via controlled ring-opening polymerization of functionalized cyclic carbonates and their application in drug delivery. , 2010, Biomaterials.

[107]  R K Jain,et al.  Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. , 1995, Cancer research.

[108]  Andrew D. Miller,et al.  DODAG; a versatile new cationic lipid that mediates efficient delivery of pDNA and siRNA. , 2010, Journal of controlled release : official journal of the Controlled Release Society.